Donnenfeld E, et al. - This trial was carried out in order to assess the safety and effectiveness of an anterior chamber intracameral dexamethasone drug-delivery suspension (IBI-10090; DEXYCU; Icon Bioscience Inc., Newark, CA) that provided medication for up to 21 days with a single application in the treatment of postoperative inflammation in individuals who underwent cataract surgery. The IBI-10090 dexamethasone drug-delivery suspension placed in the anterior chamber after cataract surgery at concentrations of 342 and 517 µg was noted to be safe and effective. It could serve as an alternative to the corticosteroid drop installation in the study cohort.